Early benefit assessment of new drugs in Germany: Framework for submission of dossiers by pharmaceutical companies.

MLA

McGauran, Natalie, et al. “Early Benefit Assessment of New Drugs in Germany: Framework for Submission of Dossiers by Pharmaceutical Companies.” Medical Writing, vol. 22, no. 3, Sept. 2013, pp. 180–85. EBSCOhost, https://doi.org/10.1179/2047480613Z.000000000133.

APA

McGauran, N., Köhler, M., & Todd, M. (2013). Early benefit assessment of new drugs in Germany: Framework for submission of dossiers by pharmaceutical companies. Medical Writing, 22(3), 180–185. https://doi.org/10.1179/2047480613Z.000000000133

Chicago

McGauran, Natalie, Michael Köhler, and Michael Todd. 2013. “Early Benefit Assessment of New Drugs in Germany: Framework for Submission of Dossiers by Pharmaceutical Companies.” Medical Writing 22 (3): 180–85. doi:10.1179/2047480613Z.000000000133.